Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells
Cancer Reports · 2026-05 · 9 (5)
DOI: 10.1002/cnr2.70568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 05.05.2026. Verfasst von Natalie Aderhold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric and Adolescent Medicine, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany. Hauptthemen laut MEDLINE: Osteosarcoma, Ribonucleotide Reductases, Bone Neoplasms, Ataxia Telangiectasia Mutated Proteins. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Osteosarcoma is the most common bone cancer in children and young adults. Its prognosis has not improved significantly since the introduction of the chemotherapy regimen established about 40 years ago, highlighting the need for new therapeutic strategies.
Aims
The present study was undertaken to assess the effectiveness of combined inhibition of two promising drug targets, ATR and ribonucleotide reductase (RNR), in osteosarcoma cells. Methods and Results The ATR inhibitor berzosertib and the RNR inhibitors triapine and didox were tested in TP53 wild‐type (U2OS, MG‐63) and mutant (SaOS‐2) osteosarcoma cell lines. Combination effects were examined by flow cytometric analysis of cell death, loss of the mitochondrial membrane potential and DNA fragmentation as well as by caspase 3/7 activity assay and real‐time RT‐PCR. The drug interactions were evaluated using combination index analysis. Single treatment with ATR or RNR inhibitors resulted in mild to moderate effects, whereas combined treatment resulted in strong and synergistic effects. ATR and RNR inhibitors cooperated to elicit loss of the mitochondrial membrane potential, to activate caspase 3/7 and to trigger DNA fragmentation, suggesting that the combination of ATR and RNR inhibitors induced an apoptotic form of cell death. The cytotoxic effects were independent of TP53 mutational status.
Conclusion
Our study demonstrates that combined inhibition of ATR and RNR was effective in osteosarcoma cells. These in vitro findings offer support for investigating in vivo the potential of a combination of ATR and RNR inhibitors as a new treatment strategy for osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric and Adolescent Medicine, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
- Research Centre Lobeda, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
- Comprehensive Cancer Centre Central Germany (CCCG), Jena, Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
ORCID-Profile: Natalie Aderhold, Lisa Immesberger, Sabine Becker, Till Milde, Bernd Gruhn, Jürgen Sonnemann
Zitieren
APA
Aderhold, N., Immesberger, L., Becker, S., Milde, T., Gruhn, B., & Sonnemann, J. (2026). Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. Cancer Reports, 9(5). https://doi.org/10.1002/cnr2.70568
Vancouver
Aderhold N, Immesberger L, Becker S, Milde T, Gruhn B, Sonnemann J. Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. Cancer Reports. 2026;9(5). doi:10.1002/cnr2.70568
BibTeX
@article{Aderhold2026,
author = {Aderhold, Natalie and Immesberger, Lisa and Becker, Sabine and Milde, Till and Gruhn, Bernd and Sonnemann, Jürgen},
title = {Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/cnr2.70568}
}
EUVIMED